Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 550 | -- | -- | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 543 | -- | -- | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,000 | -- | -- | |
| Jan 05, 2015 | VP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,667 | -- | -- | |
| Dec 04, 2014 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 89,000 | -- | -- | |
| Oct 27, 2014 | Open market or private sale of non-derivative or derivative security | Form 4 | 11,315,825 | $5.29 | -- | ||
| Sep 29, 2014 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Sep 29, 2014 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 8,000 | -- | -- | |
| Sep 29, 2014 | VP Finance and Controller | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 6,000 | -- | -- | |
| Aug 27, 2014 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.